NEW YORK, N.C., Aug. 23 (UPI) --Although they were not used in most hysterectomies, the use of electric power morcellators in the procedures has declined significantly since the U.S. Food and Drug ...

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) Among women with occult uterine sarcoma ...

Women who underwent hysterectomy for uterine fibroids experienced statistically and clinically significant increases in major and minor complications after the US Food and Drug Administration (FDA) ...

In a study appearing in the August 23/30 issue of JAMA, Jason D. Wright, M.D., of the Columbia University College of Physicians and Surgeons, New York, and colleagues examined trends in the route of ...

Philadelphia, PA, March 24, 2015 - In a new study published in the American Journal of Obstetrics & Gynecology, researchers from The University of North Carolina at Chapel Hill compared the relative ...

In late 2013, media coverage of power morcellators, a tool used during laparoscopic hysterectomies, drew attention to the controversy around the device. Patient advocates say that use of morcellators ...

SACRAMENTO (CN) - A power tool used in a hysterectomy spread cancer into a woman's abdomen, giving her seven more tumors, she claims in court. Lisa Nielsen sued Gyrus ACMI on Oct. 9. in Federal Court.

Every year, nearly 700,000 American women have surgery to remove their uterus (hysterectomy) or uterine fibroids (myomectomy). A laparoscopic surgical technique once commonly used in these procedures ...

The risk for occult gynecologic cancer in women who undergo hysterectomy or myomectomy for benign indications is low but not trivial, particularly in women older than 55 years, a new study suggests.

Researchers examined trends in the route of hysterectomy (abdominal, minimally invasive, or vaginal), use of electric power morcellators (a procedure in which the uterus is fragmented into smaller ...

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) By linking statewide hospital discharge ...

Please provide your email address to receive an email when new articles are posted on . The use of power morcellation among women undergoing minimally invasive hysterectomy significantly decreased in ...